Fresh Tracks Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
BOULDER, Colo., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the “Company” or “Fresh Tracks”) (Nasdaq: FRTX), today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.
- Historically, Fresh Tracks was a clinical-stage pharmaceutical company striving to transform patient lives through the development of innovative and differentiated prescription therapeutics.
- Revenue was $7.9 million for the third quarter of 2023, compared to $0.5 million for the third quarter of 2022.
- Research and development expenses were $0.6 million for the third quarter of 2023, compared to $3.6 million for the third quarter of 2022.
- General and administrative expenses were $5.3 million for the third quarter of 2023, compared to $3.0 million for the third quarter of 2022.